[go: up one dir, main page]

PT2694111T - Conjugados de fármaco - anticorpo - Google Patents

Conjugados de fármaco - anticorpo

Info

Publication number
PT2694111T
PT2694111T PT127112795T PT12711279T PT2694111T PT 2694111 T PT2694111 T PT 2694111T PT 127112795 T PT127112795 T PT 127112795T PT 12711279 T PT12711279 T PT 12711279T PT 2694111 T PT2694111 T PT 2694111T
Authority
PT
Portugal
Prior art keywords
antibody
drug conjugates
conjugates
drug
Prior art date
Application number
PT127112795T
Other languages
English (en)
Inventor
Manohar Khandke Kiran
Gerber Hans-Peter
Francis Dijoseph John
Ann Marquette Kimberly
Sapra* Puja
Gennadievna Tchistiakova Lioudmila
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PT2694111T publication Critical patent/PT2694111T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT127112795T 2011-04-01 2012-03-19 Conjugados de fármaco - anticorpo PT2694111T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161470576P 2011-04-01 2011-04-01
US201261593549P 2012-02-01 2012-02-01
US201261602349P 2012-02-23 2012-02-23

Publications (1)

Publication Number Publication Date
PT2694111T true PT2694111T (pt) 2016-10-20

Family

ID=45895455

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127112795T PT2694111T (pt) 2011-04-01 2012-03-19 Conjugados de fármaco - anticorpo

Country Status (27)

Country Link
US (4) US8309094B2 (pt)
EP (2) EP2694111B1 (pt)
JP (3) JP5925875B2 (pt)
KR (2) KR101529810B1 (pt)
CN (2) CN103517719B (pt)
AR (1) AR085747A1 (pt)
AU (3) AU2012235817B2 (pt)
BR (1) BR112013025186A2 (pt)
CA (1) CA2830338C (pt)
CO (1) CO6771458A2 (pt)
DK (1) DK2694111T3 (pt)
ES (1) ES2596194T3 (pt)
HK (1) HK1221153A1 (pt)
HU (1) HUE031017T2 (pt)
IL (1) IL228404A0 (pt)
MX (1) MX342860B (pt)
MY (1) MY170719A (pt)
PE (1) PE20140573A1 (pt)
PH (1) PH12013501942A1 (pt)
PL (1) PL2694111T3 (pt)
PT (1) PT2694111T (pt)
RU (1) RU2624141C2 (pt)
SA (1) SA112330402B1 (pt)
SG (2) SG10201605401WA (pt)
SI (1) SI2694111T1 (pt)
TW (2) TWI549968B (pt)
WO (1) WO2012131527A1 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
EP2287201B1 (en) 2002-03-01 2018-12-12 Immunomedics, Inc. RS7 antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
CA2508831C (en) 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
KR101443752B1 (ko) 2006-03-10 2014-09-26 와이어쓰 엘엘씨 항-５ｔ４ 항체 및 이의 용도
CN107080838A (zh) * 2010-06-04 2017-08-22 惠氏有限责任公司 疫苗制剂
DK2694111T3 (en) * 2011-04-01 2016-10-10 Wyeth Llc Antibody pharmaceutical conjugates
WO2013068874A1 (en) * 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
CN104094116B (zh) 2012-01-24 2017-05-31 辉瑞公司 在哺乳动物个体中检测5t4阳性循环肿瘤细胞的方法和诊断5t4阳性癌症的方法
CN104220595A (zh) * 2012-04-04 2014-12-17 株式会社英仙蛋白质科学 抗cdh3(p-钙粘着蛋白）抗体的药剂偶联物
ES2949376T3 (es) * 2012-10-23 2023-09-28 Synaffix Bv Anticuerpo modificado, conjugado de anticuerpo y proceso de preparación de los mismos
CN104903351A (zh) 2012-11-07 2015-09-09 辉瑞公司 抗-notch3抗体及抗体-药物缀合物
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US20240148873A1 (en) 2012-12-13 2024-05-09 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
CN104837508A (zh) 2012-12-13 2015-08-12 免疫医疗公司 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
WO2014137931A1 (en) * 2013-03-06 2014-09-12 Imaginab, Inc. Antigen binding constructs to 5t4
US9352049B2 (en) 2013-03-14 2016-05-31 Albany Molecular Research, Inc. Ligand-therapeutic agent conjugates, silicon-based linkers, and methods for making and using them
PL2991683T3 (pl) 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
WO2014197612A1 (en) 2013-06-04 2014-12-11 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US9925273B2 (en) 2013-08-01 2018-03-27 Agensys, Inc. Antibody drug conjugates (ADC) that bind to CD37 proteins
WO2015051159A1 (en) * 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
MX367851B (es) 2013-10-11 2019-09-09 Mersana Therapeutics Inc Conjugados de proteína-polímero-fármaco.
EP3054992B1 (en) * 2013-10-11 2019-08-14 Asana BioSciences, LLC Protein-polymer-drug conjugates
BR112016010051A2 (pt) 2013-11-04 2017-12-05 Pfizer ?conjugados de anticorpo-fármaco anti-efna4?
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
WO2015173133A1 (en) 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
MX374342B (es) * 2014-05-22 2025-03-06 Byondis Bv Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes.
WO2015184203A1 (en) 2014-05-29 2015-12-03 Macrogenics, Inc. Tri-specific binding molecules and methods of use thereof
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
CN107106685A (zh) 2014-10-10 2017-08-29 辉瑞公司 协同澳瑞他汀组合
US20180028658A1 (en) * 2015-02-16 2018-02-01 New York Blood Center, Inc. Antibody-drug conjugates for reducing the latent hiv reservoir
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
CN106279352B (zh) * 2015-05-29 2020-05-22 上海新理念生物医药科技有限公司 海兔毒素10的衍生物及其应用
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
TWI744261B (zh) * 2015-11-24 2021-11-01 荷蘭商拜恩迪斯公司 抗５ｔ４抗體和抗體-藥物共軛體
JP2019508023A (ja) * 2015-12-24 2019-03-28 エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド Ｔｐｂｇ抗体およびその調製方法、その共役体並び用途
US20170224837A1 (en) 2016-02-10 2017-08-10 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018119314A1 (en) * 2016-12-22 2018-06-28 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
CN108285487B (zh) * 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 抗5t4抗体-药物偶联物及其应用
CA3056542A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
WO2018183041A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
US11608384B2 (en) 2017-04-05 2023-03-21 Xdcexplorer (Shanghai) Co., Ltd. Humanized anti-TPBG antibody, preparation method therefor, conjugate thereof, and applications
WO2018210824A1 (en) * 2017-05-16 2018-11-22 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
JP2021506883A (ja) 2017-12-21 2021-02-22 メルサナ セラピューティクス インコーポレイテッド ピロロベンゾジアゼピン抗体結合体
CN110507824A (zh) 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
US20230021500A1 (en) 2018-10-29 2023-01-26 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
EP4028424A1 (en) * 2019-09-12 2022-07-20 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
AU2021240037A1 (en) 2020-03-20 2022-09-22 Immunomedics, Inc. Biomarkers for sacituzumab govitecan therapy
WO2023045141A1 (zh) * 2021-09-26 2023-03-30 上海迈泰君奥生物技术有限公司 一种双功能融合蛋白
US20230220106A1 (en) * 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
US20250154277A1 (en) * 2022-02-21 2025-05-15 Concept To Medicine Biotech Co., Ltd. Anti-5t4 antibodies and uses thereof
WO2024197151A2 (en) * 2023-03-22 2024-09-26 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
CN120361243A (zh) * 2023-08-18 2025-07-25 上海美雅珂生物技术有限责任公司 5t4抗体药物偶联物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
AR050642A1 (es) * 2004-09-10 2006-11-08 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
WO2007100385A2 (en) 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
EP1957097A1 (en) * 2005-12-06 2008-08-20 Wyeth a Corporation of the State of Delaware Interleukin-11 compositions and methods of use
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
KR101443752B1 (ko) * 2006-03-10 2014-09-26 와이어쓰 엘엘씨 항-５ｔ４ 항체 및 이의 용도
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
US8044778B2 (en) * 2007-07-12 2011-10-25 Henry Schein, Inc. Injection device and case with reporting ability
JP5394246B2 (ja) * 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
PL2211904T3 (pl) * 2007-10-19 2017-04-28 Seattle Genetics, Inc. Czynniki wiążące CD19 i ich zastosowanie
US8521761B2 (en) * 2008-07-18 2013-08-27 Google Inc. Transliteration for query expansion
WO2010111659A1 (en) 2009-03-27 2010-09-30 Wyeth Llc Tumor-initiating cells and methods for using same
DK2694111T3 (en) * 2011-04-01 2016-10-10 Wyeth Llc Antibody pharmaceutical conjugates

Also Published As

Publication number Publication date
SA112330402B1 (ar) 2015-03-18
TWI549968B (zh) 2016-09-21
AU2012235817B2 (en) 2016-03-10
BR112013025186A2 (pt) 2018-09-11
RU2624141C2 (ru) 2017-06-30
PL2694111T3 (pl) 2017-01-31
AR085747A1 (es) 2013-10-23
SI2694111T1 (sl) 2016-10-28
WO2012131527A1 (en) 2012-10-04
CA2830338C (en) 2016-11-15
US8309094B2 (en) 2012-11-13
US20170319711A1 (en) 2017-11-09
JP2014516508A (ja) 2014-07-17
MX2013011353A (es) 2013-12-16
EP2694111B1 (en) 2016-08-10
CN103517719A (zh) 2014-01-15
CN105288644A (zh) 2016-02-03
AU2012235817A1 (en) 2013-10-10
KR101783529B1 (ko) 2017-09-29
TW201534624A (zh) 2015-09-16
US20130011418A1 (en) 2013-01-10
DK2694111T3 (en) 2016-10-10
CA2830338A1 (en) 2012-10-04
EP3130356A1 (en) 2017-02-15
RU2013142004A (ru) 2015-05-10
JP2016172747A (ja) 2016-09-29
CN103517719B (zh) 2016-10-12
AU2017272321A1 (en) 2018-01-04
AU2016203839A1 (en) 2016-06-23
SG193324A1 (en) 2013-10-30
TW201302795A (zh) 2013-01-16
JP6333882B2 (ja) 2018-05-30
TWI471334B (zh) 2015-02-01
ES2596194T3 (es) 2017-01-05
PH12013501942A1 (en) 2019-11-29
EP2694111A1 (en) 2014-02-12
US8586049B2 (en) 2013-11-19
US20120251558A1 (en) 2012-10-04
HK1221153A1 (zh) 2017-05-26
KR101529810B1 (ko) 2015-06-26
SG10201605401WA (en) 2016-08-30
IL228404A0 (en) 2013-12-31
KR20150018903A (ko) 2015-02-24
MX342860B (es) 2016-10-14
JP2018140997A (ja) 2018-09-13
NZ615308A (en) 2015-10-30
US20140081005A1 (en) 2014-03-20
HK1193052A1 (zh) 2014-09-12
CO6771458A2 (es) 2013-10-15
KR20130125833A (ko) 2013-11-19
PE20140573A1 (es) 2014-05-14
MY170719A (en) 2019-08-27
HUE031017T2 (en) 2017-06-28
JP5925875B2 (ja) 2016-05-25

Similar Documents

Publication Publication Date Title
HUS2300020I1 (hu) Pirrolobenzodiazepin-antitest konjugátumok
IL263973B (en) Protein-polymer-drug conjugates
ZA201900820B (en) Antibody-drug conjugate
SG10201605401WA (en) Antibody-drug conjugates
PL2717917T3 (pl) Koniugaty p97 - przeciwciało
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
IL232936A0 (en) Antibody-drug conjugates and related compounds
EP2797959A4 (en) ASPARTYL-tRNA synthetase FC CONJUGATES
EP2776070A4 (en) IMMUNOMODULATORY CONJUGATES
EP2606072A4 (en) SYNERGISTIC BIOMOLECULAR POLYMER CONJUGATES